Results 181 to 190 of about 8,625 (250)

Real‐World Outcomes of Prophylaxis With rIX‐FP in Germany: A Prospective, Non‐Interventional Study in Haemophilia B

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Efficacy and safety of albutrepenonacog alfa (rIX‐FP) in people with haemophilia B (PwHB) has been previously demonstrated in clinical trials. However, real‐world data insights are required. Aim To describe real‐world effectiveness and tolerability of rIX‐FP in PwHB in Germany.
Johannes Oldenburg   +9 more
wiley   +1 more source

Current State of Moderate Congenital Haemophilia A and the Need for Preventive Treatment

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction The severity of haemophilia A is classified by the degree of factor VIII (FVIII) deficiency, rather than by clinical manifestations. However, FVIII activity alone does not necessarily accurately reflect clinical severity such as bleeding tendency, and patients with mild‐to‐moderate haemophilia A can experience significant disease ...
Masahiro Takeyama   +6 more
wiley   +1 more source

Underdiagnosis of Von Willebrand Disease: The Silent Majority of Women in Brazil

open access: yesHaemophilia, EarlyView.
Abstract Introduction Von Willebrand disease (VWD) is the most common inherited bleeding disorder. Although autosomal inheritance predicts a similar distribution between sexes, women are more often diagnosed due to hemostatic challenges associated with menstruation and childbirth.
Yara Maria da Silva Pires   +2 more
wiley   +1 more source

Living With Factor VII Deficiency—A Mixed Methods Study

open access: yesHaemophilia, EarlyView.
ABSTRACT Background Factor VII deficiency (FVIID) is a rare autosomal recessive disorder, resulting in potentially unpredictable and life‐threatening bleeding. The prevalence of symptomatic patients is 1 in 300,000. Treatment is mostly given following bleeding, but those with the lowest levels may be offered prophylaxis.
Simon Fletcher   +3 more
wiley   +1 more source

Pregnancy outcomes following exposure to galcanezumab: Analysis of cases from the galcanezumab clinical trials and postmarketing database

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study was conducted to describe pregnancy outcomes reported following maternal or paternal exposure to galcanezumab in clinical trials and postmarketing surveillance. Background Galcanezumab is a calcitonin gene‐related peptide‐inhibiting monoclonal antibody indicated for the preventive treatment of migraine.
Irene Boz   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy